Skip to main content

Table 2 Frequency of cardiovascular risk factors by dose regimen

From: Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Number of CVRFsa

Placebo

N = 1262

n (%)

All LTN

N = 3177

n (%)

Total

N = 4439

n (%)

0

255 (20.2)

684 (21.5)

939 (21.2)

1

486 (38.5)

1181 (37.2)

1667 (37.6)

2

326 (25.8)

837 (26.3)

1163 (26.2)

3

144 (11.4)

357 (11.2)

501 (11.3)

4

43 (3.4)

101 (3.2)

144 (3.2)

5

8 (0.6)

17 (0.5)

25 (0.6)

  1. aCVRFs were based on the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [45] and included age, total and high-density lipoprotein cholesterol, systolic blood pressure (including treated or untreated status), diabetes, and current smoking status
  2. CVRFs Cardiovascular risk factors, LTN Lasmiditan, N number of patients in the analysis population, n number of patients within each specific category
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us